T2DM is a globally prevalent disease with increasing incidence. While characterized primarily by hyperglycemia, it is also now widely acknowledged that the disease itself is more than just Hyperglycemia and that multiple other dysregulations develop concordantly with T2D. Our efforts have focused on the “Advanced” diabetics, where T2D is complicated with multiple co-morbidities driven by damage to micro and macro vasculature. Advanced Diabetics represent a large proportion of the total, with significantly higher risks of cardiovascular disease, organ damage and associated complications that stem from progressive pathology across multiple organs/tissues.
Our belief is that these increased risks cannot be addressed by controlling blood sugar alone and that the failure to address multiple metabolic parameters that are dysregulated in a these patients remains a significant gap in the clinic today.
“Next-generation” Anti-diabetics are needed that address the underlying pathology across the key metabolic tissues to provide robust and sustainable control of multiple metabolic parameters along with hyperglycemia.
Our approach to develop next-generation anti-diabetics is aimed at successfully modulating the complex cellular pathology across multiple tissues that lies at the heart of this disease. While aiming at significant therapeutic benefits from the control of metabolic parameters like Glycemic and Lipid levels and body weight, our candidates also show a direct impact on cardiovascular health through independent mechanisms.
In addition, through our programs we also seek to ameliorate critical underlying or attendant conditions that add to the risk of morbidity/mortality and deteriorating quality of life. These include chronic inflammation, poor exercise tolerance, fatty liver and loss of bone health.
By focusing on different mechanisms that contribute to the clinical phenotype, we also hope bring benefits to target specific populations that are likely to benefit from our potential therapeutics including (in different cases) the high BMI, geriatric and post-menopausal sections of Diabetics.